Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependent cytotoxicity, whereas obinutuzumab, a type II mAb, lacks the ability to redistribute into lipid rafts...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2015-03, Vol.125 (12), p.1901-1909
Hauptverfasser:	Tipton, Thomas R.W., Roghanian, Ali, Oldham, Robert J., Carter, Matthew J., Cox, Kerry L., Mockridge, C. Ian, French, Ruth R., Dahal, Lekh N., Duriez, Patrick J., Hargreaves, Philip G., Cragg, Mark S., Beers, Stephen A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived - chemistry Antibody-Dependent Cell Cytotoxicity - immunology Antigenic Modulation Antigens - chemistry Antigens, CD20 - chemistry B-Lymphocytes - immunology Female Flow Cytometry Humans Immunoglobulin G - chemistry Killer Cells, Natural - metabolism Macrophages - metabolism Mice Mice, Transgenic Phagocytosis Receptors, IgG - metabolism Rituximab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!